Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: The role of von Willebrand factor-cleaving protease

Best Practice and Research: Clinical Haematology

Volumn 14, Issue 2, 2001, Pages 437-454

  Furlan, Miha ^a   Lämmle, Bernhard ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Acquired; Constitutional; Deficiency; Haemolytic uraemic syndrome; HUS; Pathogenesis; Protease; Thrombotic thrombocytopenic purpura; TTP; von Willebrand factor; VWF

Indexed keywords

AUTOANTIBODY; CALPAIN; CYTOKINE; PLASMA PROTEIN; POLYMER; PROTEINASE; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; BINDING AFFINITY; CHILD; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEFICIENCY; FEMALE; FEVER; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFANT; KIDNEY DISEASE; MALE; MICROANGIOPATHY; MICROCIRCULATION; MICROTHROMBUS; NEUROLOGIC DISEASE; NEWBORN; PATHOGENESIS; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECURRENT DISEASE; RISK FACTOR; SYNDROME; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 0034917642     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.2001.0142     Document Type: Article

References (93)

1. The pathophysiology and management of thrombotic thrombocytopenic purpura
2. Studies on the pathophysiology of thrombotic thrombocytopenic purpura
3. Thrombotic thrombocytopenic purpura in four siblings
4. Thrombotic thrombocytopenic purpura. Occurrence two years apart during late pregnancy in two sisters
5. Thrombotic microangiopathies in the 80s: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic
6. Thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome in HLA-identical siblings
7. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome in three siblings
8. HUS and TTP: Variable expression of a single entity
9. Epidemiology of the hemolytic uremic syndrome
10. Novel platelet-agglutinating protein from a thrombotic thrombocytopenic purpura plasma
11. Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura
12. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome
13. Abnormal VIII: Von Willebrand factor patterns in the plasma of patients with the hemolytic-uremic syndrome
14. Native conformation of human von Willebrand protein. Analysis by electron microscopy and quasi-elastic light scattering
15. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor
16. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: Affinity is related to multimeric size
17. Inducible secretion of large, biologically potent von Willebrand factor multimers
18. Multimeric composition of endothelial cell-derived von Willebrand factor
19. Involvement of large plasma von Willebrand factor (VWF) multimers and unusually large VWF forms derived from endothelial cells in shear stress-induced platelet aggregation
20. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand disease
21. Heterogeneity of plasma von Willebrand factor multimers resulting from proteolysis of the constituent subunit
22. Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers
23. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis
24. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion
25. Shear stress enhances the proteolysis of von Willebrand factor in normal plasma
26. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura
27. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura
28. Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura
29. Use of vincristine in refractory thrombotic thrombocytopenic purpura
30. Vincristine sulfate for the treatment of thombotic thrombocytopenic purpura refractory to plasma-exchange
31. Vincristine as salvage treatment for refractory thrombotic thrombocytic purpura
32. Recovery by splenectomy in patients with relapsed thrombotic thrombocytopenic purpura and treatment failure to plasma exchange
33. Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura
34. Splenectomy during partial remission in thrombotic thrombocytopenic purpura with prolonged plasma exchange dependency
35. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
36. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
37. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura
38. Thrombotic thrombocytopenic purpura associated with clopidogrel
39. von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura
40. Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease
41. von Willebrand factor (VWF)-cleaving protease: Changes in health and disease
42. Verocytotoxin-I induces apoptosis in vero cells
43. Glomerular endothelial cell injury mediated by shiga-like toxin
44. The detection of shiga toxins in the kidney of a patient with hemolytic uremic syndrome
45. Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli shiga toxins 1 and 2
46. A comparison of the effects of verocytotoxin-I on primary human renal cell cultures
47. Advances in hemolytic uremic syndrome
48. Effects of verocytotoxin-I on nonadherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release
49. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome
50. Hypocomplementemic autosomal recessive hemolytic uremic syndrome with decreased factor H
51. Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Role of factor H abnormalities
52. Familial hemolytic uremic syndrome and homozygous factor H deficiency
53. Genetic studies into inherited and sporadic hemolytic uremic syndrome
54. Human complement factor H deficiency associated with hemolytic uremic syndrome
55. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome
56. von Willebrand factor-cleaving protease in childhood diarrhoea-associated hemolytic uremic syndrome
57. Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome relapse: Frequency, pathogenesis, and meaning
58. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency
59. Solvent/detergent-treated plasma suppresses shear-induced platelet aggregation and prevents episodes of thrombotic thrombocytopenic purpura
60. Chronic relapsing thrombotic thrombocytopenic purpura: Three case reports and update of the pathogenesis and therapeutic modalities
61. SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available
62. New strategies in diagnosis and treatment of thrombotic thrombocytopenic purpura: Case report and review
63. Pathologic effects of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured vascular endothelial cells
64. Lytic ant-endothelial cell antibodies in hemolytic-uremic syndrome
65. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura
66. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: Identification of an 85kD form of CD36 as a target antigen
67. Human dermal microvascular endothelial but not human umbilical vein endothelial cells express CD36 in vivo and in vitro
68. Platelet agglutinating protein p37 causes platelet activation through its binding to membrane glycoprotein IV
69. Management of thrombotic thrombocytopenic purpura
70. Anti-CD36 antibodies in patients with lupus anticoagulants and thrombotic complications
71. Minimal evidence of platelet and endothelial cell reactive antibodies in thrombotic thrombocytopenic purpura
72. Thrombotic microangiopathy and retroviral infections: A 13 year experience
73. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells
74. Detection of circulating endothelial cells in thrombotic thrombocytopenic purpura
75. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells
76. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura
77. Apoptosis of microvascular endothelial cells in the pathophysiology of thrombotic thrombocytopenic purpura/sporadic hemolytic-uremic syndrome
78. Plasma from a patient with thrombotic thrombocytopenic purpura induces endothelial cell apoptosis and platelet aggregation
79. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: In vivo and in vitro studies
80. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura
81. Circulating inflammatory cytokine levels in hemolytic uremic syndrome
82. Morphologic and ultrastructural evidence for interleukin-6 induced platelet activation
83. Calpain functions in a caspase-independent manner to promote apoptosis-like events during platelet activation
84. Membrane expression of platelet calpain
85. Evidence that activation of platelet calpain is induced as a consequence of binding of adhesive ligand to the integrin, glycoprotein IIb-IIIa
86. Inhibition of calpain blocks platelet secretion, aggregation, and spreading
87. Calcium-dependent cysteine protease activity in the sera of patients with thrombotic thrombocytopenic purpura
88. Purification of human platelet calcium-activated protease. Effect on platelet and endothelial function
89. Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: An explanation for platelet aggregation in thrombotic thrombocytopenic purpura
90. Calpain activity in patients with thrombotic thrombocytopenic purpura is associated with platelet microparticles
91. Calpain activity in bone marrow transplant-associated thrombotic thrombocytopenic purpura
92. Increased fragmentation of von Willebrand factor, due to abnormal cleavage of the subunit, parallels disease activity in recurrent hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and families
93. Hemolytic uremic syndrome - Then and now